Literature DB >> 9568824

Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition?

M Rufino1, E de Bonis, M Martín, S Rebollo, B Martín, R Miquel, M Cobo, D Hernández, A Torres, V Lorenzo.   

Abstract

Dietary intervention, phosphate (P) removal during dialysis and, especially, phosphate binders are current methods for the management of hyperphosphataemia. Ideally, the amount of P absorbed from the diet should equal the amount of P removed during dialysis, and this must occur in the context of an adequate protein intake. We evaluated the relationship between P intake and protein intake in 60 stable chronic uraemic patients (mean age 55+/-15 years, 25% diabetics, 68% males) on standard 4 h haemodialysis. The dietary counselling was relatively free for protein and calories. Nutrient intake was recorded during a 5 day period, and average daily ingestion of P and proteins was calculated using a computerized diet analysis system. A highly significant correlation was observed between protein and P intake. The mean daily ingestion of P and proteins was 998+/-316 mg and 64+/-19 g (1+/-0.4 g/kg/day), respectively. For an optimal protein diet of 1-1.2 g/kg/day, the P intake was 778-1444 mg. The amount of P removed by haemodialysis, extrapolated to an average week, is 250-300 mg/day. Since approximately 40% of P ingested is absorbed from the gut by uraemic patients treated with intestinal P binders, 750 mg of P intake should be the critical value above which a positive balance of P may occur. This value corresponds to a protein intake of 45-50 g per day (>0.8 g/kg body weight/day for a 60 kg patient). In patients undergoing standard chronic haemodialysis, a neutral P balance is difficult to achieve, despite phosphate binder therapy, when protein intake is >50 g. Additional protein restriction, in order to obtain a neutral balance, may impose the risk of protein malnutrition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568824     DOI: 10.1093/ndt/13.suppl_3.65

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Dietary phosphorus intake and distribution in Chinese peritoneal dialysis patients with and without hyperphosphatemia.

Authors:  Na Jiang; Wei Fang; Xiaoxiao Yang; Lin Zhang; Jiangzi Yuan; Aiwu Lin; Zhaohui Ni; Jiaqi Qian
Journal:  Clin Exp Nephrol       Date:  2014-09-05       Impact factor: 2.801

Review 3.  Reexamining the Phosphorus-Protein Dilemma: Does Phosphorus Restriction Compromise Protein Status?

Authors:  David E St-Jules; Kathleen Woolf; Mary Lou Pompeii; Kamyar Kalantar-Zadeh; Mary Ann Sevick
Journal:  J Ren Nutr       Date:  2016-02-09       Impact factor: 3.655

Review 4.  Phosphate control in end-stage renal disease: barriers and opportunities.

Authors:  Ahmed A Waheed; Fernando Pedraza; Oliver Lenz; Tamara Isakova
Journal:  Nephrol Dial Transplant       Date:  2013-07-30       Impact factor: 5.992

5.  Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.

Authors:  Wan-Chuan Tsai; Hon-Yen Wu; Yu-Sen Peng; Shih-Ping Hsu; Yen-Ling Chiu; Ju-Yeh Yang; Hung-Yuan Chen; Mei-Fen Pai; Wan-Yu Lin; Kuan-Yu Hung; Fang-Yeh Chu; Shu-Min Tsai; Kuo-Liong Chien
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-13       Impact factor: 8.237

6.  Prescribed dietary phosphate restriction and survival among hemodialysis patients.

Authors:  Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 8.237

7.  Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics.

Authors:  Sunil V Badve; Deborah L Zimmerman; Greg A Knoll; Kevin D Burns; Brendan B McCormick
Journal:  Clin J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 8.237

Review 8.  Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Authors:  Víctor Lorenzo Sellares; Armando Torres Ramírez
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Authors:  Felix Bronner; Boris M Slepchenko; Michael Pennick; Stephen J P Damment
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.